HIV ||| S:0 E:3 ||| NNP
/ ||| S:3 E:4 ||| NNP
HCV-coinfection ||| S:4 E:19 ||| NNP
:  ||| S:19 E:21 ||| :
which  ||| S:21 E:27 ||| WDT
role  ||| S:27 E:32 ||| NN
can  ||| S:32 E:36 ||| MD
new  ||| S:36 E:40 ||| JJ
antiretrovirals  ||| S:40 E:56 ||| JJ
such  ||| S:56 E:61 ||| JJ
as  ||| S:61 E:64 ||| IN
integrase  ||| S:64 E:74 ||| JJ
inhibitors  ||| S:74 E:85 ||| JJ
play ||| S:85 E:89 ||| NN
?  ||| S:89 E:91 ||| .
End-stage  ||| S:91 E:101 ||| JJ
liver  ||| S:101 E:107 ||| NN
disease  ||| S:107 E:115 ||| NN
has  ||| S:115 E:119 ||| VBZ
become  ||| S:119 E:126 ||| VBN
one  ||| S:126 E:130 ||| CD
of  ||| S:130 E:133 ||| IN
the  ||| S:133 E:137 ||| DT
most  ||| S:137 E:142 ||| RBS
frequent  ||| S:142 E:151 ||| JJ
causes  ||| S:151 E:158 ||| NNS
of  ||| S:158 E:161 ||| IN
death  ||| S:161 E:167 ||| NN
in  ||| S:167 E:170 ||| IN
HIV ||| S:170 E:173 ||| NNP
/ ||| S:173 E:174 ||| NNP
HCV-coinfected  ||| S:174 E:189 ||| JJ
patients ||| S:189 E:197 ||| NNS
.  ||| S:197 E:199 ||| .
The  ||| S:199 E:203 ||| DT
role  ||| S:203 E:208 ||| NN
of  ||| S:208 E:211 ||| IN
new  ||| S:211 E:215 ||| JJ
antiretrovirals  ||| S:215 E:231 ||| NN
in  ||| S:231 E:234 ||| IN
the  ||| S:234 E:238 ||| DT
progression  ||| S:238 E:250 ||| NN
of  ||| S:250 E:253 ||| IN
liver  ||| S:253 E:259 ||| JJ
fibrosis  ||| S:259 E:268 ||| NN
has  ||| S:268 E:272 ||| VBZ
yet  ||| S:272 E:276 ||| RB
to  ||| S:276 E:279 ||| TO
be  ||| S:279 E:282 ||| VB
defined ||| S:282 E:289 ||| VBN
.  ||| S:289 E:291 ||| .
However  ||| S:291 E:299 ||| RB
with  ||| S:299 E:304 ||| IN
significant  ||| S:304 E:316 ||| JJ
toxicities  ||| S:316 E:327 ||| NN
and  ||| S:327 E:331 ||| CC
drug-to-drug  ||| S:331 E:344 ||| JJ
interactions  ||| S:344 E:357 ||| NNS
of  ||| S:357 E:360 ||| IN
nucleoside  ||| S:360 E:371 ||| JJ
reverse  ||| S:371 E:379 ||| JJ
transcriptase  ||| S:379 E:393 ||| JJ
inhibitors  ||| S:393 E:404 ||| NN
in  ||| S:404 E:407 ||| IN
combination  ||| S:407 E:419 ||| NN
with  ||| S:419 E:424 ||| IN
ribavirin ||| S:424 E:433 ||| NN
,  ||| S:433 E:435 ||| ,
with  ||| S:435 E:440 ||| IN
drug  ||| S:440 E:445 ||| NN
to  ||| S:445 E:448 ||| TO
drug  ||| S:448 E:453 ||| NN
interaction  ||| S:453 E:465 ||| NN
of  ||| S:465 E:468 ||| IN
HIV  ||| S:468 E:472 ||| NNP
protease  ||| S:472 E:481 ||| VBD
inhibitors  ||| S:481 E:492 ||| VBN
with  ||| S:492 E:497 ||| IN
HCV  ||| S:497 E:501 ||| NNP
protease  ||| S:501 E:510 ||| NN
inhibitors  ||| S:510 E:521 ||| NNS
and  ||| S:521 E:525 ||| CC
calcineurin-inhibitors ||| S:525 E:547 ||| JJ
,  ||| S:547 E:549 ||| ,
new  ||| S:549 E:553 ||| JJ
antiretrovirals  ||| S:553 E:569 ||| NNS
lacking  ||| S:569 E:577 ||| VBG
these  ||| S:577 E:583 ||| DT
interactions  ||| S:583 E:596 ||| NNS
represent  ||| S:596 E:606 ||| VBP
attractive  ||| S:606 E:617 ||| JJ
alternatives  ||| S:617 E:630 ||| NNS
in  ||| S:630 E:633 ||| IN
the  ||| S:633 E:637 ||| DT
setting  ||| S:637 E:645 ||| NN
of  ||| S:645 E:648 ||| IN
anti-HCV  ||| S:648 E:657 ||| JJ
therapy  ||| S:657 E:665 ||| NN
or  ||| S:665 E:668 ||| CC
post  ||| S:668 E:673 ||| VB
liver  ||| S:673 E:679 ||| JJ
transplantation ||| S:679 E:694 ||| NN
.  ||| S:694 E:696 ||| .
In  ||| S:696 E:699 ||| IN
the  ||| S:699 E:703 ||| DT
following  ||| S:703 E:713 ||| JJ
review  ||| S:713 E:720 ||| NN
we  ||| S:720 E:723 ||| PRP
want  ||| S:723 E:728 ||| VBP
to  ||| S:728 E:731 ||| TO
focus  ||| S:731 E:737 ||| VB
on  ||| S:737 E:740 ||| IN
the  ||| S:740 E:744 ||| DT
new  ||| S:744 E:748 ||| JJ
class  ||| S:748 E:754 ||| NN
of  ||| S:754 E:757 ||| IN
HIV  ||| S:757 E:761 ||| NNP
integrase  ||| S:761 E:771 ||| NN
inhibitors  ||| S:771 E:782 ||| NNS
and  ||| S:782 E:786 ||| CC
discuss  ||| S:786 E:794 ||| VB
present  ||| S:794 E:802 ||| JJ
data  ||| S:802 E:807 ||| NNS
with  ||| S:807 E:812 ||| IN
regard  ||| S:812 E:819 ||| NN
to  ||| S:819 E:822 ||| TO
special  ||| S:822 E:830 ||| JJ
issues  ||| S:830 E:837 ||| NNS
of  ||| S:837 E:840 ||| IN
HIV  ||| S:840 E:844 ||| NNP
and  ||| S:844 E:848 ||| CC
HCV  ||| S:848 E:852 ||| NNP
co-infection ||| S:852 E:864 ||| NNP
.  ||| S:864 E:866 ||| .
